The product Xolair has a history that goes back several decades. It was originally approved in 2003 for the treatment of moderate to severe asthma. The drug was subsequently granted marketing ...

Xolair (omalizumab) is a prescription drug used to treat certain conditions, such as asthma or food allergies. The drug comes as an injection. It’s usually given once every 2 or 4 weeks.

CHICAGO (WGN) — For decades, asthma patients have used a drug ... The most common side effects of Xolair are injection site reactions and fever, but the FDA noted that the drug has also been ...

"This study really looked at preventing accidental ingestions, preventing anaphylaxis, and just making life a little easier ...

Britain’s National Institute for Health and Clinical Excellence (NICE) has decided to withdraw its recommendation for asthma drug, Xolair, citing that a review of up-to-date clinical trial data ...

The FDA has approved a new prefilled syringe formulation for Roche’s asthma drug Xolair, as the Swiss company ... in the US and EU as a subcutaneous injection lasting a few minutes, instead ...

is the first and only omalizumab biosimilar referencing Xolair® approved in Canada to treat multiple allergic diseases including chronic idiopathic urticaria (CIU), allergic asthma, and chronic ...

Korea's pharmaceutical giant Celltrion said Monday that it has received approval from Canadian health authorities for a biosimilar treatment for allergic asthma ... a version of Xolair, has ...